Diagonal Therapeutics is pioneering a novel approach to agonist antibody therapeutics, focusing on reactivating critical biological pathways to address the root causes of debilitating diseases. Unlike traditional antibodies that inhibit cellular functions, Diagonal's agonist antibodies activate signaling cascades by binding to two receptors in a specific conformation, which facilitates their activation. The company has developed a proprietary platform that combines advanced computational and experimental techniques, allowing for the rapid exploration of billions of binding combinations to identify agonists with high fidelity. This innovative approach enables the generation of deep immune repertoires containing approximately 200,000 distinct antibody sequences, which can be clustered and optimized to produce multispecific antibodies with over 10 billion possible combinations.

The platform's versatility has been demonstrated across various receptor families, making it applicable for designing agonist antibodies to treat multiple diseases. Diagonal Therapeutics is currently advancing candidates for conditions such as Hereditary Hemorrhagic Telangiectasia (HHT) and Pulmonary Arterial Hypertension (PAH), where their agonist antibodies have shown promise in preclinical models by reactivating essential signaling pathways and restoring vascular homeostasis. The company emphasizes the advantages of antibody therapeutics, including high specificity and manufacturability, as they progress their lead candidates toward human clinical trials.

United States

Diagonal Therapeutics is a biotech company pioneering a new approach to discovering and developing agonist antibodies. The Company's DIAGONAL platform combines proprietary computational and experimental techniques to overcome historical challenges associated with agonist antibody drug discovery. Diagonal's emerging pipeline – discovered using the DIAGONAL platform – has the potential to deliver life-changing therapies to patients including therapies for hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension.

Diagonal Therapeutics

Company Details